LENZ Therapeutics Achieves 19% Prescription Growth, $1.9M Q1 Revenue and Expands Sales Territories
LENZ Therapeutics reported Q1 2026 revenue of $1.9M, including $1.7M from VIZZ® on 25,000 paid prescriptions (19% rise from Q4 2025) with 46,000 prescriptions filled. The company holds $258.4M cash, is expanding sales territories to 117, launched a Sarah Jessica Parker DTC ad, and filed MAAs in Europe and UK.
1. Q1 Financial Performance
LENZ Therapeutics recorded total revenue of $1.9 million in Q1 2026, driven by $1.7 million in VIZZ® product sales on 25,000 paid prescriptions (a 19% increase from Q4 2025). License revenue of $0.2 million reflected an upfront payment from the Lunatus agreement. The company held $258.4 million in cash and equivalents as of March 31, 2026, funding operations to expected positive cash flow post-launch.
2. Prescription and Market Adoption
Since launch, LENZ has filled approximately 46,000 paid prescriptions, representing 1.2 million daily doses, with more than 10,000 unique eye care professionals prescribing VIZZ®. About 60% of these prescribers have written multiple orders, indicating growing practitioner confidence and demand for the therapy.
3. Sales Force Expansion and DTC Campaign
To support rising demand, LENZ is expanding its sales force from 88 to 117 territories, aiming for full deployment by end of Q2 2026, and has initiated a direct sales program enabling ECPs to dispense VIZZ® directly. The January DTC campaign featuring Sarah Jessica Parker drove website traffic tenfold, with pilot TV ads rolling out in select markets in April 2026.
4. International Expansion and Regulatory Filings
LENZ submitted Marketing Authorization Applications for VIZZ® to the EMA in March 2026 and to the MHRA in April 2026, marking its fifth and sixth ex-U.S. filings. The exclusive distribution deal with Lunatus for the Middle East provided a $0.2 million upfront payment and positions LENZ to earn further regulatory and commercial milestones as the product launches internationally.